BRCA2 reversion mutations as a resistance mechanism to olaparib in patients with BRCA2-mutated mCRPC: a case series

Hereditary Cancer in Clinical Practice · Published 2026-07-28 · DOI 10.1186/s13053-026-00346-x

Free full text

Authors (6)

Kohji Takemura, Ayumi Abe, Kazushige Sakaguchi, Shinji Urakami, Masami Arai, Yuji Miura

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Takemura, K., Abe, A., Sakaguchi, K., et al. (2026). BRCA2 reversion mutations as a resistance mechanism to olaparib in patients with BRCA2-mutated mCRPC: a case series. Hereditary Cancer in Clinical Practice. https://doi.org/10.1186/s13053-026-00346-x

Related articles

• Fear of cancer recurrence in breast cancer survivors carrying a BRCA1 or 2 genetic mutation : a cross-sectional study · Hereditary Cancer in Clinical Practice · 2024 · Same journal
• Awareness of hereditary breast cancer and readiness for genetic testing among newly diagnosed patients with breast cancer in Nigeria: a multicentre study · Hereditary Cancer in Clinical Practice · 2026 · Same journal
• Medullary breast cancer and germline BRCA1 mutations: a possible criterion for genetic testing · Hereditary Cancer in Clinical Practice · 2025 · Same journal
• Meeting abstracts from the Annual Conference “Clinical Genetics of Cancer 2023” · Hereditary Cancer in Clinical Practice · 2024 · Same journal
• Tumour mutational burden using a targeted panel approach for comprehensive tumour profiling focusing on colorectal cancer · Hereditary Cancer in Clinical Practice · 2025 · Same journal
• Primary and metastatic brain tumours in hereditary cancer syndromes: case reports with and literature review · Hereditary Cancer in Clinical Practice · 2026 · Same journal
• Clinical characteristics and healthcare burden of neurofibromatosis type 1 in Saudi Arabia: a single centre experience · Hereditary Cancer in Clinical Practice · 2025 · Same journal
• Genomic profiling in Bulgarian women with ovarian cancer: a dual-sample NGS approach · Hereditary Cancer in Clinical Practice · 2026 · Same journal
• The psychosocial impact of receiving a polygenic risk score informing risk of prostate cancer · Hereditary Cancer in Clinical Practice · 2026 · Same journal
• High familial risks in some rare cancers may pinpoint to hidden germline genetics: focus on esophageal, stomach, small intestinal, testis, thyroid and bone cancers · Hereditary Cancer in Clinical Practice · 2025 · Same journal